Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

In-depth discussion of stratification of Company's 2(nd) line data of Annamycin as a therapy for acute myeloid leukemia (AML)

Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study

HOUSTON, March 20, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2023, on Friday afternoon, March 22, 2024. Moleculin management will host a conference call and live webcast to discuss clinical, operational and financial results on Monday morning, March 25, 2024 at 8:30 AM ET.

Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Moleculin website,, and will be archived for 90 days.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit and connect on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
(833) 475-8247

View original content to download multimedia:

SOURCE Moleculin Biotech, Inc.